Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

2.50
Hdl Handle:
http://hdl.handle.net/10757/622260
Title:
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Authors:
Khunger, Monica; Rakshit, Sagar; Pasupuleti, Vinay; Hernandez, Adrian V. ( 0000-0002-9999-4003 ) ; Mazzone, Peter; Stevenson, James; Pennell, Nathan A.; Velcheti, Vamsidhar
Citation:
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer 2017, 152 (2):271 Chest
Publisher:
Elsevier Inc
Journal:
Chest
Issue Date:
Aug-2017
URI:
http://hdl.handle.net/10757/622260
DOI:
10.1016/j.chest.2017.04.177
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0012369217308826
Abstract:
Background Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they are often associated with potentially fatal immune-mediated pneumonitis. Preliminary reports of trials suggest a difference in the rate of pneumonitis with PD-1 and PD-L1 inhibitors. We sought to determine the overall incidence of pneumonitis and differences according to type of inhibitors and prior chemotherapy use. Methods MEDLINE, Embase, and Scopus databases were searched up to November 2016. Rates of pneumonitis of any grade and grade ≥ 3 from all clinical trials investigating nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab as single agents in NSCLC were collected. The incidence of pneumonitis across trials was calculated using DerSimonian-Laird random effects models. We compared incidences between PD-1 and PD-L1 inhibitors and between treatment naive and previously treated patients. Results Nineteen trials (12 with PD-1 inhibitors [n = 3,232] and 7 with PD-L1 inhibitors [n = 1,806]) were identified. PD-1 inhibitors were found to have statistically significant higher incidence of any grade pneumonitis compared with PD-L1 inhibitors (3.6%; 95% CI, 2.4%-4.9% vs 1.3%; 95% CI, 0.8%-1.9%, respectively; P =.001). PD-1 inhibitors were also associated with higher incidence of grade 3 or 4 pneumonitis (1.1%; 95% CI, 0.6%-1.7% vs 0.4%; 95% CI, 0%-0.8%; P =.02). Treatment naive patients had higher incidence of grade 1 through 4 pneumonitis compared with previously treated patients (4.3%; 95% CI, 2.4%-6.3% vs 2.8%; 95% CI, 1.7%- 4%; P =.03). Conclusions There was a higher incidence of pneumonitis with use of PD-1 inhibitors compared with PD-L1 inhibitors. Higher rate of pneumonitis was more common in treatment naive patients. © 2017 American College of Chest Physicians
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/restrictedAccess
Language:
eng
Description:
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Keywords:
Immune-related adverse events; Immunotherapy; Meta-analysis; Non-small cell lung cancer; Antineoplastic agent; atezolizumabavelumab; CD274 protein, human; Durvalumab; Monoclonal antibody; Nivolumab; PDCD1 protein, human; Pembrolizumab
ISSN:
00123692
Email:
velchev@ccf.org

Full metadata record

DC FieldValue Language
dc.contributor.authorKhunger, Monicaes
dc.contributor.authorRakshit, Sagares
dc.contributor.authorPasupuleti, Vinayes
dc.contributor.authorHernandez, Adrian V.es
dc.contributor.authorMazzone, Peteres
dc.contributor.authorStevenson, Jameses
dc.contributor.authorPennell, Nathan A.es
dc.contributor.authorVelcheti, Vamsidhares
dc.date.accessioned2017-10-19T16:18:07Z-
dc.date.available2017-10-19T16:18:07Z-
dc.date.issued2017-08-
dc.identifier.citationIncidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer 2017, 152 (2):271 Chestes
dc.identifier.issn00123692-
dc.identifier.doi10.1016/j.chest.2017.04.177-
dc.identifier.urihttp://hdl.handle.net/10757/622260-
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es_PE
dc.description.abstractBackground Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they are often associated with potentially fatal immune-mediated pneumonitis. Preliminary reports of trials suggest a difference in the rate of pneumonitis with PD-1 and PD-L1 inhibitors. We sought to determine the overall incidence of pneumonitis and differences according to type of inhibitors and prior chemotherapy use. Methods MEDLINE, Embase, and Scopus databases were searched up to November 2016. Rates of pneumonitis of any grade and grade ≥ 3 from all clinical trials investigating nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab as single agents in NSCLC were collected. The incidence of pneumonitis across trials was calculated using DerSimonian-Laird random effects models. We compared incidences between PD-1 and PD-L1 inhibitors and between treatment naive and previously treated patients. Results Nineteen trials (12 with PD-1 inhibitors [n = 3,232] and 7 with PD-L1 inhibitors [n = 1,806]) were identified. PD-1 inhibitors were found to have statistically significant higher incidence of any grade pneumonitis compared with PD-L1 inhibitors (3.6%; 95% CI, 2.4%-4.9% vs 1.3%; 95% CI, 0.8%-1.9%, respectively; P =.001). PD-1 inhibitors were also associated with higher incidence of grade 3 or 4 pneumonitis (1.1%; 95% CI, 0.6%-1.7% vs 0.4%; 95% CI, 0%-0.8%; P =.02). Treatment naive patients had higher incidence of grade 1 through 4 pneumonitis compared with previously treated patients (4.3%; 95% CI, 2.4%-6.3% vs 2.8%; 95% CI, 1.7%- 4%; P =.03). Conclusions There was a higher incidence of pneumonitis with use of PD-1 inhibitors compared with PD-L1 inhibitors. Higher rate of pneumonitis was more common in treatment naive patients. © 2017 American College of Chest Physicianses
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherElsevier Inces
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0012369217308826es
dc.rightsinfo:eu-repo/semantics/restrictedAccesses
dc.subjectImmune-related adverse eventses
dc.subjectImmunotherapyes
dc.subjectMeta-analysises
dc.subjectNon-small cell lung canceres
dc.subjectAntineoplastic agentes
dc.subjectatezolizumabavelumabes
dc.subjectCD274 protein, humanes
dc.subjectDurvalumabes
dc.subjectMonoclonal antibodyes
dc.subjectNivolumabes
dc.subjectPDCD1 protein, humanes
dc.subjectPembrolizumabes
dc.titleIncidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Canceres
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalChestes
dc.description.peerreviewRevisión por pareses_PE
dc.contributor.emailvelchev@ccf.orges_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.